Thyroid Hormones and Insulin Testing in Pediatrics
Customize your policy alerts
Sign up for Arizona Complete Health Policy CP.MP.154 alerts
Get alerted when Policy CP.MP.154 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and coding guidance for thyroid (TSH, T3, T4) and insulin testing in children age 1–18, focusing on routine testing in healthy or obese-but-otherwise-healthy pediatric patients for plans affiliated with Centene Corporation/Arizona Complete Health.
No material clinical or coverage changes in this revision.
Coverage Criteria — Thyroid and Insulin Testing (Pediatrics)
Not medically necessary — routine testing
Applies to testing billed with CPT/ICD combinations listed in coding tables.
Insulin measurement lacks standardized assays and clinically useful thresholds in youth; considered a research tool.
The policy does not list specific clinical exceptions within Criteria I or II. However, professional guideline recommendations are acknowledged: endocrine evaluation may be appropriate when growth parameters are abnormal. Specifically, the Endocrine Society and the American Academy of Pediatrics recommend targeted endocrine assessment when a child’s stature and/or height velocity are attenuated relative to their genetic/familial potential and pubertal stage. In those situations, focused testing guided by clinical findings — rather than routine population screening — is the advised approach.
Providers should therefore consider endocrine referral or targeted laboratory assessment only when clinical indicators of endocrine disease are present (for example, abnormal growth pattern or delayed/precocious pubertal development). Routine, untargeted testing in asymptomatic children is not supported by guideline recommendations and is not covered by this policy.
Routine thyroid hormone testing and routine insulin testing in otherwise healthy pediatric patients age 1–18 years, including those who are obese but otherwise healthy, are not medically necessary because these tests have not been demonstrated to provide clear clinical benefit. The policy applies when the listed CPT codes are billed with the corresponding ICD-10-CM codes in the coding tables.
The coding tables enumerate specific procedure codes for thyroid and insulin assays (see Table 1) and diagnosis codes for well child/obesity encounters (see Table 2). Claims for the CPT/ICD-10-CM pairings shown may be denied as not medically necessary; inclusion of codes in the tables is informational and does not alone guarantee coverage.
Coding — CPT and ICD-10-CM Guidance
| 83525 | Insulin; total. |
| 83527 | Insulin; free. |
| 84436 | Thyroxine; total. |
| 84439 | Thyroxine; free. |
| 84443 | Thyroid stimulating hormone (TSH). |
| 84479 | Thyroid hormone (T3 or T4) uptake or thyroid hormone binding ratio (THBR). |
| 84480 | Triiodothyronine T3; total (TT-3). |
| 84481 | Triiodothyronine T3; free. |
| 84482 | Triiodothyronine T3; reverse |
Provider Actions, Billing Rules, and Denial Risk
Not medically necessary code pairing
Not medically necessary code pairing — The CPT codes listed in Table 1 when billed with the corresponding ICD-10-CM diagnosis codes in Table 2 are considered not medically necessary.
Provider coding reminder
Provider-focused reminder — Providers should review coding guidance prior to claim submission and ensure tests are billed with accurate diagnosis codes reflecting medical necessity.
Documentation and plan/state/federal precedence
Documentation and precedence note — Providers must document medical necessity consistent with plan coverage documents and applicable state and federal requirements. Coverage decisions are subject to the member's evidence of coverage, contract terms, and any state Medicaid precedence where applicable.
Denial risk for routine pediatric thyroid/insulin testing
Denial risk for routine testing — Claims for routine thyroid or insulin testing in otherwise healthy pediatric patients (age ≥ 1 and ≤ 18) billed with the CPT codes listed in Table 1 and diagnosis codes listed in Table 2 are at risk for denial.
Background — Clinical Context
Thyroid hormones regulate numerous metabolic processes via the hypothalamic–pituitary–thyroid axis. T4 (thyroxine) is the major secreted hormone of the thyroid and is converted peripherally to T3 (triiodothyronine); secretion of T4 is regulated by pituitary TSH. Disruption of the feedback loop can lead to hypo- or hyperthyroid states, which are diagnosed and managed based on clinical assessment combined with targeted hormone quantification.
In pediatrics, however, interpretation of thyroid and insulin laboratory values is complicated by associations with obesity and by assay limitations. TSH and total T4 may be elevated in children who are overweight or obese without clear evidence that these findings denote primary thyroid disease. Fasting insulin concentrations have substantial overlap between insulin-resistant and insulin-sensitive youths, lack standardized assays and reproducible thresholds, and therefore are of limited clinical utility for routine evaluation of obesity; measurement is considered primarily a research tool.
Definitions and Test Limitations
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.